clinical trial · NCT07364214
Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)
Healthy ParticipantsQuemliclustat
brief summary
The purpose of the study is to investigate the routes of elimination and overall mass balance of 100 mg quemliclustat containing 75 μCi \[14C\] following a single IV infusion of \[14C\]-quemliclustat in healthy adult male participants, and to quantify total radioactivity (TRA) in plasma, whole blood, urine, and feces.
started
Feb 3, 2026
primary completion
Apr 6, 2026
completion
Apr 6, 2026
last updated
May 1, 2026
official title
A Phase 1, Open-Label Study to Characterize the Metabolism, Excretion, and Mass Balance of a Single Intravenous Dose of 100 mg Containing 75 µCi of [14C]-Quemliclustat in Healthy Adult Male Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol